Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
US |
|
Ballard Power Systems Inc
TSX:BLDP
|
CA |
|
Summit Hotel Properties Inc
NYSE:INN
|
US |
|
Fortnox AB
STO:FNOX
|
SE |
|
Damodar Industries Ltd
NSE:DAMODARIND
|
IN |
|
Benchmark Metals Inc
XTSX:BNCH
|
CA |
|
SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
|
IN |
|
V
|
Voss Veksel og Landmandsbank ASA
OSE:VVL
|
NO |
|
X Fab Silicon Foundries EV
PAR:XFAB
|
BE |
|
Kiplin Metals Inc
F:17G1
|
CA |
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. The company is headquartered in Nashville, Tennessee and currently employs 83 full-time employees. The company went IPO on 2009-08-11. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. The company is headquartered in Nashville, Tennessee and currently employs 83 full-time employees. The company went IPO on 2009-08-11. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.
New product: Cumberland entered a joint commercialization and ownership arrangement with RedHill for Talicia (H. pylori treatment); Cumberland will invest $2 million in 2025 and $2 million in 2026 and will equally share U.S. net revenues while handling U.S. distribution and promotion.
Revenue: Q3 net revenue from continuing operations was $8.3 million and year-to-date revenue through September was $30.9 million; management noted Q4 is typically the strongest quarter.
Pipeline progress: Ifetroban reported positive topline FIGHT DMD Phase II results (high-dose showed a 3.3% overall LVEF improvement versus placebo decline), an End-of-Phase II meeting with the FDA was held and follow-on interactions are planned; enrollment is complete in systemic sclerosis study and IPF Phase II enrollment is underway.
Vibativ momentum: Vibativ added to Vizient and Premier purchasing agreements, 4-vial starter pack launched, and commercial launches progressing internationally (Saudi Arabia live; China approval earlier in the year).
Profitability & cash: Q3 net loss was $1.9 million; operating cash flow was nearly $5 million year-to-date; cash and equivalents were $15.2 million with $66 million in total assets at quarter end.
Acquisitions: Vibativ and Sancuso acquisitions added material inventory and intangibles (Vibativ: ~$21 million inventory, $12 million intangibles; Sancuso: ~$4 million inventory, $12 million intangibles) and required upfront and milestone payments.
Commercial challenges: Kristalose faces increased pharmacy substitution from generics; management is implementing strategies to protect and grow that business.
Balance sheet: Total liabilities were $40 million (including $5 million drawn on a $20 million credit facility), shareholders' equity $26 million, and total debt reduced by $10 million since the end of 2024.
